Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC increased its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 171.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 165,397 shares of the biotechnology company’s stock after acquiring an additional 104,448 shares during the period. Anika Therapeutics makes up approximately 3.8% of Stonepine Capital Management LLC’s holdings, making the stock its 7th largest holding. Stonepine Capital Management LLC owned about 1.13% of Anika Therapeutics worth $4,190,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Invenomic Capital Management LP lifted its position in shares of Anika Therapeutics by 124.6% during the fourth quarter. Invenomic Capital Management LP now owns 210,332 shares of the biotechnology company’s stock worth $4,766,000 after purchasing an additional 116,679 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Anika Therapeutics by 25.8% in the 1st quarter. Acadian Asset Management LLC now owns 421,427 shares of the biotechnology company’s stock worth $10,701,000 after buying an additional 86,436 shares in the last quarter. Meros Investment Management LP boosted its position in Anika Therapeutics by 25.0% in the 2nd quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock valued at $5,388,000 after buying an additional 42,587 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Anika Therapeutics by 6.9% during the second quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after acquiring an additional 38,412 shares in the last quarter. Finally, Boston Partners purchased a new stake in shares of Anika Therapeutics during the first quarter worth about $733,000. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Price Performance

ANIK opened at $24.70 on Tuesday. Anika Therapeutics, Inc. has a 12-month low of $17.88 and a 12-month high of $29.11. The stock has a market capitalization of $360.30 million, a PE ratio of -4.70 and a beta of 0.83. The firm’s fifty day moving average price is $25.69 and its 200 day moving average price is $25.86.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). The company had revenue of $41.92 million during the quarter, compared to analyst estimates of $39.90 million. Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. During the same quarter last year, the company posted ($0.06) EPS. On average, equities research analysts forecast that Anika Therapeutics, Inc. will post -0.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Barrington Research reissued an “outperform” rating and issued a $37.00 price target on shares of Anika Therapeutics in a report on Friday, August 9th.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.